Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SKIN vs HNST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HNST Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–2 Matrix Metrics)

HNST Overall Winner 6-Pillar Tally: SKIN 2 – 4 HNST Matrix Metrics: SKIN 2 – 7 HNST

As of Nov 16, 2026, The Honest Company, Inc. (HNST) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas HNST carries 36.7/100 (SELL) at $4.88 (43.5x Forward P/E, 2.4% operating margin).

  • Defensive Composite Rating Caution: Although HNST compares more favorably head-to-head, both SKIN (34.1/100 SELL) and HNST (36.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SKIN vs HNST
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24
HNST NASDAQ Head-to-Head Winner
The Honest Company, Inc. Common Stock
Retail-Catalog & Mail-Order Houses
$4.88
-2.79% 1D
Market Cap $547.1M
TTM Revenue $334M
Forward P/E 43.5x
Beta / 30D Vol 1.09β · 66% Vol
Unified Composite Score
36.7 / 100 SELL
Tech 17.0 Fund 46.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.3 · SMA20: $4.74 · SMA50: $5.03

6-Pillar Scorecard Institutional Category Breakdown (SKIN 2 – 4 HNST)

Columns: Metric · SKIN · HNST
1. Valuation Multiples HNST
Forward P/E 106.4x 43.5x
Trailing P/E 106.4x 7.3x
PEG Ratio 0.93x N/M
EV / Revenue 0.9x 1.4x
2. Growth & Scale SKIN
Revenue Growth (YoY) -2.1% -8.6%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $289M $334M
Market Cap $106.3M $547.1M
3. Profitability & Quality HNST
Gross Margin 67.2% 42.4%
Operating Margin 2.4% 2.4%
Net Profit Margin -6.3% 23.5%
Return on Equity (ROE) -30.1% 34.6%
4. Balance Sheet & Cash Flow HNST
Cash Generation (TTM) $17M $49M
Cash Flow Margin 5.8% 14.5%
Net Cash / Leverage $161M Net Debt (6.61x D/E) $96M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HNST
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 517.4% (100th %ile) 68.0% (7th %ile)
Put/Call OI Skew N/A 0.46x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.8% of Rev ($187M) 40.0% of Rev ($134M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Household & Personal Products Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SKIN (2) vs HNST (7)
Institutional Metric SKIN HNST Criterion Row Edge
Market Capitalization
Scale
$106.3M $547.1M Larger Scale HNST
Trailing P/E Ratio
Valuation
106.4x 7.3x Lower Multiple HNST
Forward P/E Ratio
Valuation
106.4x 43.5x Lower Multiple HNST
Revenue Growth (YoY)
Growth
-2.1% -8.6% Higher Growth SKIN
Operating Margin (TTM)
Profitability
2.4% 2.4% Higher Margin Tie
Net Profit Margin
Profitability
-6.3% 23.5% Higher Margin HNST
Return on Equity (ROE)
Capital Efficiency
-30.1% 34.6% Higher ROE HNST
52-Week Range Position
Momentum
83% ($0–$18) 71% ($2–$6) Stronger Trend SKIN
Beta / 30D Volatility
Risk Regime
-14.22β · 192% Vol 1.09β · 66% Vol Lower Realized Risk HNST
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 36.7 / 100 (SELL) Higher Composite HNST
Trailing 12M Revenue (USD)
Operating Scale
$289M $334M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.2% 42.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 0.9x EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M ($161M Net Debt (6.61x D/E)) $49M ($96M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +45.02 pp
SKIN: +42.52% · HNST: -2.5%
3M Horizon SKIN +2405.7 pp
SKIN: +2408.33% · HNST: +2.63%
6M Horizon SKIN +2336.06 pp
SKIN: +2385.14% · HNST: +49.08%
1Y Horizon SKIN +969.47 pp
SKIN: +1057.69% · HNST: +88.22%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SKIN Revenue HNST Revenue SKIN Op. Margin HNST Op. Margin Margin Leader
FY2019 $170M $240M 8.1% -13.4% SKIN
FY2020 $120M $300M -14.4% -4.5% HNST
FY2021 $260M $320M -15.4% -11.6% HNST
FY2022 $370M $310M -7.1% -15.9% SKIN
FY2023 $400M $340M -32.9% -11.3% HNST
FY2024 $330M $380M -20.3% -1.7% HNST
FY2025 $300M $370M -6.9% -5.0% HNST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HNST CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 68.0%
IV Percentile 7th %ile
Put/Call OI Skew 0.46x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact HNST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published
HNST Moat Profile Scale & Operating Efficiency Moat
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $547.1M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 40.0% of Rev ($134M)
90D Engineering Disclosures 0 Published

Investor FAQ SKIN vs HNST Key Questions & Quantitative Answers

As of Nov 16, 2026, The Honest Company, Inc. (HNST) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas HNST carries 36.7/100 (SELL) at $4.88 (43.5x Forward P/E, 2.4% operating margin). Defensive Composite Rating Caution: Although HNST compares more favorably head-to-head, both SKIN (34.1/100 SELL) and HNST (36.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SKIN leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with HNST at -8.6% YoY revenue growth and N/A YoY earnings growth on $334M TTM revenue (42.4% gross margin, 2.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), SKIN cumulative revenue shifted +76.5% while HNST shifted +54.2%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 40.0% of Rev ($134M) (0 disclosures) for HNST.

HNST screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas HNST trades at 43.5x Forward P/E, 7.3x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus HNST (34.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, HNST carries 68.0% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.46x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.09β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.